Vit Kraushaar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vit Kraushaar has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alex R. Hoffmaster
Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4018, USA
1 shared publication - Brian T. Richardson
Centers for Disease Control and Prevention, Bacterial Special Pathogens Branch , Atlanta, Georgia
1 shared publication - Caitlin M. Cossaboom
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication - Caroline A. Schrodt
Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention , Atlanta, Georgia
1 shared publication - Catherine M. Brown
Massachusetts Department of Public Health, Boston, MA 02130, USA
1 shared publication - Christina T. Egan
New York State Department of Health, Albany, NY 12208, USA
1 shared publication
Latest Publications
- Open Access
Occupational Laboratory Exposures to Burkholderia pseudomallei in the United States: A Review of Exposures and Serological Monitoring Data, 2008–2024
Infection with Burkholderia pseudomallei, the causative agent of melioidosis, is uncommon in the United States (U.S.), leading to delays in pathogen identification and clinical diagnosis which can often lead to laboratory exposures. The indirect hemagglutination assay (IHA) is the primary serological test for confirming exposure to B. pseudomallei. In the U.S., a titer of ≥1:40 suggests exposure to B. pseudomallei or a closely related species, and a 4-fold rise in IHA titer ≥1:40 with clinically compatible illness is considered diagnostically probable. A retrospective analysis of 160 voluntarily reported laboratory exposure events to B. pseudomallei across 29 U.S. jurisdictions and 5 countries between 2008–2024 was conducted. This analysis included post-exposure management data and IHA results for 855 exposed laboratory personnel who had serological monitoring performed at the U.S. Centers for Disease Control and Prevention (CDC). Among exposed laboratory personnel, 105 (12%) had a seropositive titer. Of these, ninety-one (87%) laboratory personnel remained seropositive (≥1:40) at their last IHA test. Five (1%) people had a 4-fold rise in titers, though none developed melioidosis. This report underscores the need for prospective studies to evaluate seropositive laboratory personnel and to update risk guidance for laboratory exposures in non-endemic areas.
Open AccessOccupational Laboratory Exposures to Burkholderia pseudomallei in the United States: A Review of Exposures and Serological Monitoring Data, 2008–2024
Infection with Burkholderia pseudomallei, the causative agent of melioidosis, is uncommon in the United States (U.S.), leading to delays in pathogen identification and clinical diagnosis which can often lead to laboratory exposures. The indirect hemagglutination assay (IHA) is the primary serological test for confirming exposure to B. pseudomallei. In the U.S., a titer of ≥1:40 suggests exposure to B. pseudomallei or a closely related species, and a 4-fold rise in IHA titer ≥1:40 with clinically compatible illness is considered diagnostically probable. A retrospective analysis of 160 voluntarily reported laboratory exposure events to B. pseudomallei across 29 U.S. jurisdictions and 5 countries between 2008–2024 was conducted. This analysis included post-exposure management data and IHA results for 855 exposed laboratory personnel who had serological monitoring performed at the U.S. Centers for Disease Control and Prevention (CDC). Among exposed laboratory personnel, 105 (12%) had a seropositive titer. Of these, ninety-one (87%) laboratory personnel remained seropositive (≥1:40) at their last IHA test. Five (1%) people had a 4-fold rise in titers, though none developed melioidosis. This report underscores the need for prospective studies to evaluate seropositive laboratory personnel and to update risk guidance for laboratory exposures in non-endemic areas.